CytRx Corp. (CYTR) – CEO Steven A. Kriegsman at the Helm
CytRx Corp. (CYTR) – CEO Steven A. Kriegsman at the Helm
Los Angeles-based CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The
company’s oncology pipeline is focused on the clinical development of aldoxorubicin, its improved version of the widely
used chemotherapeutic agent doxorubicin. The company also has rights to two additional drug candidates, tamibarotene and
bafetinib.
At the helm of the company’s strong management team is president and CEO Steven A. Kriegsman, who has held the post since
2002. He also serves as a director of Galena Biopharma, Inc. (GALE) and chairman of Galena’s Compensation and Transaction
Committees. Kriegsman previously served as director and chairman of Global Genomics from June 2000.
Kriegsman also is an inactive chairman and founder of Kriegsman Capital Group LLC, a financial advisory firm specializing
in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He
has advised such companies as SuperGen, Inc., Closure Medical Corporation, Novoste Corp., Advanced Tissue Sciences, and
Maxim Pharmaceuticals.
Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in
Mergers and Acquisitions at New York University, The Management Institute. Kriegsman is a graduate of the Stanford Law
School Directors’ College. He was formerly a Certified Public Accountant with KPMG in New York City, and served as a
director and is the former chairman of the Audit Committee of Bradley Pharmaceuticals, Inc..
In 2006, Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS
Association, and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy
Association. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of
Technology (Caltech), Brown University and New York University. He has also been active in various charitable
organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association,
the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies,
and the Palisades-Malibu YMCA.
For more information, see the company website at www.cytrx.com.
Please read full disclaimers at https://disclaimer.missionir.com